Expression of the SART3 Tumor-Rejection Antigen in Brain Tumors and Induction of Cytotoxic T Lymphocytes by Its Peptides

The authors recently reported on the SART3 tumor-rejection antigen, which possesses epitopes that can induce cytotoxic T lymphocytes (CTLs) in patients with epithelial cancer. To explore a new modality for treatment of patients with brain tumors, this study investigated the expression of the SART3 antigen in patients with brain tumors and the ability of SART3 peptides to induce CTLs from peripheral blood mononuclear cells (PBMCs) of these patients. The SART3 antigen was detected in the cytoplasmic fraction of all 18 glioma cell lines examined and in the majority (31 of 34; 91%) of brain tumor tissues irrespective of their histologies. It was also expressed in the nuclear fraction of all 18 glioma cell lines and in the majority (26 of 34; 76%) of brain tumor tissues. In contrast, the SART3 was not expressed in nontumorous brain tissues. Cytotoxic T lymphocytes were induced in patients with glioma by stimulation with two epitope peptides of SART3. These CTLs could eliminate glioma cells in a HLA-A24–restricted manner. Therefore, the SART3 peptides may be appropriate molecules for use in peptide-based specific immunotherapy of HLA-A24+ patients with brain tumors.

[1]  M. Shigemori,et al.  Expression of the tumor‐rejection antigen SART1 in brain tumors , 1999, International journal of cancer.

[2]  K. Shirouzu,et al.  Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. , 1999, Cancer research.

[3]  P. Walker,et al.  Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. , 1999, International immunology.

[4]  H. Yamana,et al.  Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes , 1999, International journal of cancer.

[5]  K. Itoh,et al.  A newly identified MAGE‐3‐derived epitope recognized by HLA‐A24‐restricted cytotoxic T lymphocytes , 1999, International journal of cancer.

[6]  K. Ushijima,et al.  Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer , 1999, Cancer Immunology, Immunotherapy.

[7]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[8]  S. Shichijo,et al.  Expression of the SART‐1 tumor rejection antigen in breast cancer , 1999, International journal of cancer.

[9]  M. Sakamoto,et al.  Expression of the SART‐1 Antigens in Uterine Cancers , 1998, Japanese journal of cancer research : Gann.

[10]  Moses Rodriguez,et al.  Theiler's virus infection of genetically susceptible mice induces central nervous system-infiltrating CTLs with no apparent viral or major myelin antigenic specificity. , 1998, Journal of immunology.

[11]  D. Hinton,et al.  CTL effector function within the central nervous system requires CD4+ T cells. , 1998, Journal of immunology.

[12]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[13]  H. Yamana,et al.  A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[14]  S. Oka,et al.  Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. , 1997, Journal of immunology.

[15]  P. Walker,et al.  Immunobiology of Gliomas: New Perspectives for Therapy a , 1997, Annals of the New York Academy of Sciences.

[16]  S. Rosenberg,et al.  The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. , 1997, Journal of immunology.

[17]  D L Morton,et al.  Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. , 1997, The American journal of pathology.

[18]  T. Kuramoto.  Detection of MAGE-1 tumor antigen in brain tumor. , 1997, The Kurume medical journal.

[19]  M. Nakao,et al.  Higher susceptibility of erythropoietin-producing renal cell carcinomas to lysis by lymphokine-activated killer cells. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[20]  V. Ravi,et al.  Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. , 1996, The Journal of general virology.

[21]  E. Appella,et al.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.

[22]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[23]  P. Coulie,et al.  A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.

[24]  T. Owens,et al.  Inflammatory cytokines in the brain: does the CNS shape immune responses? , 1994, Immunology today.

[25]  Y. Miyagi,et al.  Modulation of tumor immunogenicity of rat glioma cells by s-Myc expression: eradication of rat gliomas in vivo. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[26]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[27]  M. Hart,et al.  Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. , 1994, Immunology today.

[28]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[29]  P. Romero,et al.  The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. , 1993, International journal of cancer.

[30]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[31]  A. V. von Eschenbach,et al.  Human renal‐cell carcinoma cells are able to activate natural killer cells , 1992, International journal of cancer.

[32]  T. Honjo,et al.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[34]  R. Finberg,et al.  Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells , 1991, Journal of virology.

[35]  C. Morris,et al.  Mononuclear cell infiltration in central portions of human astrocytomas. , 1988, Journal of neurosurgery.

[36]  H. Weiner,et al.  In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis , 1987, Annals of neurology.

[37]  伊藤 雅昭.  Identification of SART3-derived Peptides Capable of Inducing HLA-A2-restricted and Tumor-specific CTLs in Cancer Patients with Different HLA-A2 Subtypes , 2001 .

[38]  K. Tadokoro,et al.  Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes , 1997, Immunogenetics.

[39]  S. Rosenberg,et al.  Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. , 1996, Advances in cancer research.

[40]  M. Tykocinski,et al.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. , 1993, Science.

[41]  P. Knopf,et al.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. , 1992, Immunology today.